Log Out

Encompass Health (NYSE:EHC) Price Target Cut to $62.00 by Analysts at Credit Suisse Group

Defense World · Sep 22, 2022 04:22

Encompass Health (NYSE:EHC – Get Rating) had its target price cut by Credit Suisse Group from $63.00 to $62.00 in a research note published on Wednesday, Marketbeat Ratings reports. They currently have an outperform rating on the stock.

Several other analysts also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Encompass Health from $80.00 to $62.00 in a report on Wednesday, August 3rd. Truist Financial reduced their price target on shares of Encompass Health from $75.00 to $65.00 and set a buy rating on the stock in a report on Monday, August 8th. Barclays reduced their price target on shares of Encompass Health from $80.00 to $63.00 and set an overweight rating on the stock in a report on Thursday, August 4th. Raymond James reduced their price target on shares of Encompass Health from $70.00 to $65.00 and set a strong-buy rating on the stock in a report on Thursday, August 4th. Finally, Royal Bank of Canada cut their price objective on shares of Encompass Health from $82.00 to $66.00 in a research report on Wednesday, August 24th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Encompass Health has an average rating of Buy and an average price target of $70.00.

Get Encompass Health alerts:

Encompass Health Stock Down 2.3 %

EHC stock opened at $48.87 on Wednesday. The company has a market cap of $4.88 billion, a P/E ratio of 14.94, a P/E/G ratio of 2.43 and a beta of 1.02. Encompass Health has a 52 week low of $44.33 and a 52 week high of $78.31. The company's 50-day moving average price is $50.78 and its 200 day moving average price is $59.30. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 1.29.

Encompass Health (NYSE:EHC – Get Rating) last released its quarterly earnings data on Monday, August 1st. The company reported $0.89 EPS for the quarter, missing analysts' consensus estimates of $0.97 by ($0.08). The company had revenue of $1.33 billion for the quarter, compared to analysts' expectations of $1.34 billion. Encompass Health had a return on equity of 16.20% and a net margin of 6.22%. The firm's quarterly revenue was up 3.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.17 EPS. On average, research analysts expect that Encompass Health will post 2.88 earnings per share for the current fiscal year.

Encompass Health Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, October 17th. Investors of record on Monday, October 3rd will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 1.23%. The ex-dividend date is Friday, September 30th. Encompass Health's dividend payout ratio (DPR) is 34.25%.

Insider Buying and Selling

In related news, CEO Mark J. Tarr sold 20,449 shares of the company's stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $53.25, for a total transaction of $1,088,909.25. Following the completion of the transaction, the chief executive officer now owns 440,895 shares of the company's stock, valued at $23,477,658.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Encompass Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Baupost Group LLC MA grew its stake in Encompass Health by 318.9% during the first quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company's stock worth $213,330,000 after buying an additional 2,283,900 shares during the period. State Street Corp grew its stake in Encompass Health by 5.0% during the first quarter. State Street Corp now owns 2,733,254 shares of the company's stock worth $195,118,000 after buying an additional 130,504 shares during the period. Victory Capital Management Inc. grew its stake in Encompass Health by 40.0% during the second quarter. Victory Capital Management Inc. now owns 2,146,910 shares of the company's stock worth $120,335,000 after buying an additional 613,547 shares during the period. Bank of New York Mellon Corp grew its stake in Encompass Health by 33.3% during the first quarter. Bank of New York Mellon Corp now owns 2,099,763 shares of the company's stock worth $149,314,000 after buying an additional 524,766 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Encompass Health by 88.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,685,880 shares of the company's stock worth $94,494,000 after buying an additional 792,813 shares during the period. Institutional investors and hedge funds own 93.07% of the company's stock.

About Encompass Health

(Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.